+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Anemia Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4760537
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Akebia Therapeutics
  • Amgen, Inc.
  • FibroGen, Inc.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • MORE
The Anemia Treatment Drugs market was valued at USD 23,155.8 Mn in 2017 and is expected to grow at a CAGR of 16.4% during the forecast period 2018 to 2026.

Market Insights
According to the American Society of Hematology, anemia is the most common hematological disorder and affects more than 3 million Americans every year. The global scenario is more concerning because the World Health Organization states that globally around 1.62 billion people get affected by anemia, which is equal to 22.5% of the global population. In addition to that highest prevalence of anemia was found in the preschool-age children, and the lowest prevalence is in men. Furthermore, the highest number of individuals affected with anemia after pre-school-age children are non-pregnant women which are around 31.2% of the total anemic population. The treatment specifically depends on the type of anemia and other complications associated with it. Currently, the treatment for anemia specifically focuses on supplements and chronic conditions are directly treated with blood transfusion, stem cell transplant or bone marrow transplant.

The major types of anemia that are treated with drugs are Iron deficiency anemia, thalassemia, aplastic anemia, hemolytic anemia, sickle cell anemia, and pernicious anemia. In the year 2017, iron deficiency anemia and sickle cell anemia dominated the market together accounting for nearly 60% of the market share. The key factors responsible for the growth of these two types of anemia are sickle cell anemia & aplastic anemia has the highest prevalence, and the available drug treatment costs more compared to other types. These two types of anemia are expected to maintain their dominance throughout the forecast period due to the expected market entry of more than 10 molecules during the forecast period from 2018 to 2026.

The anemia treatment drugs market comprises drugs such as vitamins & iron supplements, antibiotics, immunosuppressant, bone marrow stimulants, corticosteroids, gene therapy & iron chelating agents. In 2017, immunosuppressant & corticosteroids accounted for a combined market share of 58% due to key market driving factors such as the rising prevalence of anemia, increasing awareness related to anemia with the initiative of government & non-government organizations, and incessant advancement in the research & development of anemia treatment industry. The drug pipeline of anemia treatment is very strong and several prominent players are present along with their promising molecules. The most efficient molecules present in the drug pipeline are FG-4592/roxadustat (FibroGen), Daprodustat/GSK1278863 (GlaxoSmithKline), Molidustat/BAY85-3934 (Bayer), Rivipansel (Pfizer), Luspatercept (Celgene), OMS721 (Omeros Corporation), and LentiGlobin BB305 (bluebird bio). Thus, such as strong drug pipeline is expected to drive the overall anemia treatment drugs market significantly throughout the forecast period.

Market Competition Assessment

The anemia treatment drugs market is expected to grow significantly in the near future and there are several companies operating in this market and expected to enter the market. The overall competitive scenario is expected to observe a paradigm shift towards gene therapy & monoclonal antibody therapies. The key players present in this market are Pfizer, Inc., Amgen, Inc., Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen Pharmaceutical, Bayer AG, AMAG Pharmaceuticals, GlaxoSmithKline plc, Akebia Therapeutics, Vifor Pharma Management, Ltd., and FibroGen, Inc. among others.

Key Market Movements
  • An increasing prevalence of anemia and its types in developed as well as developing countries
  • Rising awareness in developing countries due to initiative and programs introduced by the government and non-government organizations
  • Incessant development in the field of research and development in anemia treatment
  • The major competition for the available drugs is from stem cell transplantation and upcoming pipeline drugs in the near future
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Akebia Therapeutics
  • Amgen, Inc.
  • FibroGen, Inc.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Anemia Treatment Drugs Market Portraiture
2.2. Global Anemia Treatment Drugs Market, by Type of Anemia, 2017 (US$ Mn)
2.3. Global Anemia Treatment Drugs Market, by Type of Drug, 2017 (US$ Mn)
2.4. Global Anemia Treatment Drugs Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Anemia Treatment Drugs Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Rising prevalence of anemia and complications related with diseases related to anemia
3.2.2. Increasing awareness related to anemia diagnosis and treatment especially in developing and under developed countries from Asia, Africa & South America
3.3. Challenges
3.3.1. Chronic anemia is treated with bone marrow transplantation or blood transfusion there no drug treatment available in the market
3.4. Opportunities
3.4.1. Strong pipeline with number of promising molecules that will drive the overall anemia treatment drugs market in the near future
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Anemia Treatment Drugs Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Iron deficiency anemia
4.3. Thalassemia
4.4. Aplastic anemia
4.5. Hemolytic anemia
4.6. Sickle cell anemia
4.7. Pernicious anemia

Chapter 5. Global Anemia Treatment Drugs Market, by Type of Drug, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Supplements
5.3. Antibiotics
5.4. Immunosuppresants
5.5. Bone Marrow Stimulants
5.6. Corticosteroids
5.7. Gene Therapy
5.8. Iron Chelating Agents
5.9. Pipeline Analysis: Global Anemia Treatment Drugs Market
5.9.1. Overview
5.9.2. Phase III Drugs: Market Size Forecast till 2026 (US$ Mn)
5.9.2.1. FG-4592/Roxadustat (FibroGen)
5.9.2.2. Daprodustat/GSK1278863 (GlaxoSmithKline)
5.9.2.3. Molidustat/BAY85-3934 (Bayer)
5.9.2.4. MT-6548 (Mitsubishi Tanabe Pharma Corporation)
5.9.2.5. Rivipansel/GMI-1070 (Pfizer)
5.9.2.6. Luspatercept (Celgene)
5.9.2.7. AG-348 (Agios Pharmaceuticals, Inc.)
5.9.2.8. Sutimlimab (Bioverativ Therapeutics Inc.)
5.9.2.9. V114 (Merck Sharp & Dohme Corp.)
5.9.2.10. LentiGlobin/BB305 (bluebird bio)
5.9.2.11. APL-2 (Apellis Pharmaceuticals, Inc.)
5.9.2.12. ALXN1210 (Alexion Pharmaceuticals)
5.9.2.13. OMS721 (Omeros Corporation)
5.9.3. Phase II (Tabular Representation)
5.9.4. Phase I (Tabular Representation)

Chapter 6. Global Anemia Treatment Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America Anemia Treatment Drugs Market Analysis, 2016 – 2026
6.2.1. North America Anemia Treatment Drugs Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.2.2. North America Anemia Treatment Drugs Market, by Type of Drug, 2016–2026 (US$ Mn)
6.2.3. North America Anemia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Anemia Treatment Drugs Market Analysis, 2016 – 2026
6.3.1. Europe Anemia Treatment Drugs Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.3.2. Europe Anemia Treatment Drugs Market, by Type of Drug, 2016–2026 (US$ Mn)
6.3.3. Europe Anemia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Anemia Treatment Drugs Market Analysis, 2016 – 2026
6.4.1. Asia Pacific Anemia Treatment Drugs Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific Anemia Treatment Drugs Market, by Type of Drug, 2016–2026 (US$ Mn)
6.4.3. Asia Pacific Anemia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of APAC
6.5. Latin America Anemia Treatment Drugs Market Analysis, 2016 – 2026
6.5.1. Latin America Anemia Treatment Drugs Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.5.2. Latin America Anemia Treatment Drugs Market, by Type of Drug, 2016–2026 (US$ Mn)
6.5.3. Latin America Anemia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Anemia Treatment Drugs Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa Anemia Treatment Drugs Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.6.2. Middle East & Africa Anemia Treatment Drugs Market, by Type of Drug, 2016–2026 (US$ Mn)
6.6.3. MEA Anemia Treatment Drugs Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Hoffmann-La Roche Ltd.
7.3. Novartis AG
7.4. Pfizer, Inc.
7.5. Janssen Pharmaceuticals, Inc.
7.6. Teva Pharmaceutical Industries, Ltd.
7.7. AMAG Pharmaceuticals
7.8. Rockwell Medical
7.9. Akebia Therapeutics
7.10. Vifor Pharma Management, Ltd.
7.11. FibroGen, Inc.
7.12. GlaxoSmithKline plc
7.13. Bayer AG
7.14. Omeros Corporation
7.15. Merck Sharp & Dohme Corp.

List of Figures
Figure 1 Anemia Treatment Drugs: Market Segmentation
Figure 2 Global Anemia Treatment Drugs Market Share, by Type of Anemia, 2017 (US$ Mn)
Figure 3 Global Anemia Treatment Drugs Market Share, by Type of Drug, 2017 (US$ Mn)
Figure 4 Global Anemia Treatment Drugs Market, by Geography, 2017 Vs 2026 (Value %)
Figure 5 Attractive Investment Proposition, by Geography, 2017
Figure 6 Market Competition Landscape, by Key Players, 2017
Figure 7 Global Iron Deficiency Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 8 Global Thalassemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 9 Global Aplastic Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 10 Global Hemolytic Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 11 Global Sickle Cell Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 12 Global Pernicious Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 13 Global Supplements Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
Figure 14 Global Antibiotics Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
Figure 15 Global Immunosuppressant Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
Figure 16 Global Bone Marrow Stimulants Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
Figure 17 Global Corticosteroids Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
Figure 18 Global Gene Therapy Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
Figure 19 Global Iron Chelating Agents Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
Figure 20 U.S. Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 21 Canada Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 22 U.K. Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 23 Germany Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 24 Rest Of Europe Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 25 Japan Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 26 China Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 27 Rest Of Asia Pacific Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 28 Brazil Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 29 Mexico Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 30 Rest Of Latin America Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 31 GCC Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
Figure 32 Rest Of Middle East And Africa Anemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)

List of Tables
Table 1 Global Anemia Treatment Drugs Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
Table 2 Global Anemia Treatment Drugs Market, by Type of Drug, 2016 – 2026 (US$ Mn)
Table 3 North America Anemia Treatment Drugs Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
Table 4 North America Anemia Treatment Drugs Market, by Type of Drug, 2016 – 2026 (US$ Mn)
Table 5 North America Anemia Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 6 Europe Anemia Treatment Drugs Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
Table 7 Europe Anemia Treatment Drugs Market, by Type of Drug, 2016 – 2026 (US$ Mn)
Table 8 Europe Anemia Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 9 Asia Pacific Anemia Treatment Drugs Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
Table 10 Asia Pacific Anemia Treatment Drugs Market, by Type of Drug, 2016 – 2026 (US$ Mn)
Table 11 Asia Pacific Anemia Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 12 Latin America Anemia Treatment Drugs Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
Table 13 Latin America Anemia Treatment Drugs Market, by Type of Drug, 2016 – 2026 (US$ Mn)
Table 14 Latin America Anemia Treatment Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
Table 15 Middle East & Africa Anemia Treatment Drugs Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
Table 16 Middle East & Africa Anemia Treatment Drugs Market, by Type of Drug, 2016 – 2026 (US$ Mn)
Table 17 Middle East And Africa Anemia Treatment Drugs Market, by Region, 2016 – 2026 (US$ Mn)
Table 18 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 19 Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 21 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 22 Janssen Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 23 Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 24 AMAG Pharmaceuticals : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 25 Rockwell Medical : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 26 Akebia Therapeutics : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 27 Vifor Pharma Management, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 28 FibroGen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 29 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 30 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 31 Omeros Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 32 Merck Sharp & Dohme Corp. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen, Inc.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries, Ltd.
  • AMAG Pharmaceuticals
  • Rockwell Medical
  • Akebia Therapeutics
  • Vifor Pharma Management, Ltd.
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Bayer AG
  • Omeros Corporation
  • Merck Sharp & Dohme Corp.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760537
Adroll
adroll